Developers of CD70.CAR using human CD27

Adicet Bio is a clinical-stage biotechnology company pioneering the development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. The company's lead oncology candidate, ADI-270, is an "off-the-shelf" CAR-T therapy that targets CD70-positive tumors using a binding domain derived from the natural human CD27 receptor. This approach is designed to enhance tumor specificity and effector function by mimicking natural ligand-receptor interactions, potentially offering superior performance over traditional scFv-based CARs. Adicet is also advancing ADI-101, a dual-targeting CD19/CD20 gamma delta CAR-T cell therapy, for both B-cell malignancies and autoimmune indications such as lupus nephritis. By leveraging the unique innate and adaptive immune properties of gamma delta T cells, Adicet aims to create durable, potent, and scalable therapies for a wide range of high-unmet-need conditions.